Plain-English translation of NCT06565026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CS-206, an experimental treatment for severe sickle cell disease. The treatment works by taking your own blood stem cells, editing them in a laboratory to help them produce more fetal hemoglobin (a type of hemoglobin normally found in babies), and then giving them back to you. The hope is that increased fetal hemoglobin can reduce the painful and dangerous complications of sickle cell disease.
Current treatments for severe sickle cell disease either require finding a matching donor (which is difficult and not always possible) or carry serious risks of complications. This medication offers a new approach by using your own cells, avoiding the need for a donor match and the associated risks.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will first collect your blood stem cells through a procedure called apheresis. These cells will then be sent to a laboratory where they will be genetically edited using specialized technology. After the editing is complete, the modified cells will be returned to your body through an infusion. You will need to attend regular follow-up visits to monitor how well the treatment works and to check for any side effects. The study will involve frequent blood tests and medical evaluations over an extended period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CorrectSequence Therapeutics Co., Ltd
Collaborators
First Affiliated Hospital of Guangxi Medical University
Enrollment target
~5 participants
Started
September 2024
Primary completion
December 2026
Age range
12 Years – 35 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yaliang Li
First Affiliated Hospital of Guangxi Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.